12
Participants
Start Date
December 26, 2023
Primary Completion Date
October 10, 2024
Study Completion Date
December 20, 2024
XKH001 Injection
Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Kanova Biopharmaceutical Co., LTD
INDUSTRY